Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

    NEXT STORY
    Merus to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
    PREV STORY
    G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules Capital
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    OSE Immunotherapeutics Announces Presentation at The 19th Annual Rodman & Renshaw Global Investment Conference In New York City, September 10-12, 2017

    NANTES, France, Aug. 31, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE), today ...

    author_avatar
    NASDAQ Market News

    Summit Therapeutics to Participate in 2018 BTIG Healthcare Conference

    OXFORD, United Kingdom, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), ...

    author_avatar
    NASDAQ Market News

    Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panels

    SAN DIEGO, May 09, 2018 (GLOBE NEWSWIRE) -- Invivoscribe Technologies Inc., a global precision diagnostics ...

    author_avatar
    NASDAQ Market News